Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia's Parliament, establishes a regulatory framework to ensure the safety, quality, and efficacy of therapeutic goods within the country. This Act addresses the problem of ensuring that only licensed manufacturers can produce therapeutic goods, thereby safeguarding public health by preventing substandard or counterfeit products from entering the market. The Act aims to maintain a high standard of therapeutic goods available to consumers and ensures that manufacturers comply with stringent regulatory requirements. The Therapeutic Goods Administration, as the delegate of the Secretary of the Department of Health, is responsible for the administration and enforcement of the Act. In this context, the revocation of a licence to manufacture therapeutic goods, as published in the Gazette on 2 July 2018 by David Rowbury, underscores the Act's objective of maintaining regulatory compliance. Specifically, the revocation of licences for Select Foods Pty Ltd and McKinnon Direct Packaging & Fulfilment Pty Ltd due to non-payment of annual licence charges exemplifies the enforcement mechanism in place to uphold the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, importation, supply, and advertising of therapeutic goods within Australia. This legislation encompasses a broad range of entities including corporations, partnerships, and individuals who are engaged in activities related to therapeutic goods. The Act's jurisdiction extends across the Commonwealth of Australia, with the Therapeutic Goods Administration (TGA) overseeing compliance and enforcement. Notably, the Act applies to the entire lifecycle of therapeutic goods, from their development and manufacture to their distribution and post-market surveillance. Exclusions and exemptions may apply in certain circumstances, particularly for research and small-scale manufacturing activities, as specified under the Act and its subordinate instruments. The revocation of manufacturing licences, as exemplified in the gazette, highlights the Act’s stringent enforcement mechanisms aimed at maintaining high standards of safety and efficacy in the therapeutic goods market. The Act's provisions can be extended or further defined through regulations and guidelines issued by the TGA, thereby providing a comprehensive regulatory framework to ensure public health and safety.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") includes various provisions concerning the regulation of therapeutic goods, including the licensing of manufacturers. Section 41(1)(f) allows the Secretary of the Department of Health to revoke a manufacturer's licence if the annual licence charges are not paid. This section is pertinent to the revocation of licences held by Select Foods Pty Ltd and McKinnon Direct Packaging & Fulfilment Pty Ltd, as stated in the notice issued by David Rowbury, the Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration. Under the Act, entities such as Select Foods Pty Ltd and McKinnon Direct Packaging & Fulfilment Pty Ltd are required to pay annual licence charges to maintain their status as licensed manufacturers of therapeutic goods. This obligation is essential to ensure that manufacturers comply with regulatory standards and are capable of producing therapeutic goods safely and effectively. Failure to meet this requirement can result in the revocation of their licence, as seen in the notice, which details the specific circumstances leading to the revocation for non-payment of these charges. The notice issued under section 41(1)(f) serves as formal notification that the licences of Select Foods Pty Ltd and McKinnon Direct Packaging & Fulfilment Pty Ltd have been revoked. This revocation means that these entities can no longer legally manufacture therapeutic goods until their licences are reinstated. The notice also provides specific details, including the licence numbers and addresses of the affected companies, to ensure clarity and accountability in the regulatory process. In terms of consequences for non-compliance, the Act does not explicitly state the penalties for non-payment of annual licence charges within the provided notice. However, it is clear that the failure to pay these charges can lead to the revocation of a manufacturer's licence, which can severely impact the entity's ability to operate in the therapeutic goods market. It is essential for manufacturers to adhere to their obligations under the Act to avoid such regulatory actions.